

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor(s):	Zoltan Kiss	Examiner:	
Appln. No.:	10/582,391	Group Art Unit:	
Filing Date:	June 9, 2006	Confirmation No.:	
Title:	METHOD FOR IMPROVING INSULIN SENSITIVITY BY ADMINISTERING AN INHIBITOR OF ANTITRYPsin	Customer No.:	25764
		Docket No.:	59496 - 336756

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

I CERTIFY THAT THIS CORRESPONDENCE IS BEING ELECTRONICALLY
TRANSMITTED TO THE U.S. PATENT AND TRADEMARK OFFICE ON
DECEMBER 29, 2006.

Amber Friend
Amber Friend

INFORMATION DISCLOSURE STATEMENT

In compliance with the duty imposed by 37 C.F.R. 1.56, and in accordance with C.F.R. sections 1.97 *et seq.*, the materials enclosed herewith are brought to the attention of the Examiner as possibly being of interest in connection with the above-identified patent application. Consideration of each of the documents listed on the attached SB/08 form(s) is respectfully requested. The filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the statement is, or is construed to be, prior art or material to the patentability of the present application.

This Information Disclosure Statement is being filed before the receipt of an Office Action on the merits. No fee is believed to be necessary. However, should any fee be required, the Commissioner is authorized to charge our Deposit Account No. 06-0029 and is requested to notify us of the same.

Respectfully submitted,

FAEGRE & BENSON LLP

By:

Tanya S. D'Souza
Tanya S. D'Souza, Reg. No. 56,948
612/766-7835 Customer No.: 25764

Dated: December 29, 2006

fb.us.1726342.01

fb.us.1726342.01

<p>Substitute for form 1449A/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p><i>(Use as many sheets as necessary)</i></p>				Complete if Known	
				Application Number	10/582,391
				Filing Date	December 9, 2004
				First Named Inventor	Zoltan Kiss
				Art Unit	1618
				Examiner Name	Shirley V. Gembeh
Sheet	1	of	4	Attorney Docket Number	59496 - 336756

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Signature	/Shirley Gembeh/	Date Considered	08/06/2009
-----------------------	------------------	--------------------	------------

***EXAMINER:** initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/582,391
(Use as many sheets as necessary)				Filing Date	July 14, 2006
				First Named Inventor	Zoltan Kiss
				Art Unit	1618
				Examiner Name	Shirley V. Gembeh
Sheet	2	of	4	Attorney Docket Number	59496 - 336756

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
/S.G./		ZIMMET et al., "Global and societal implications of the diabetes epidemic," <i>Nature</i> 414 , pp. 782-787, 2001			
		SALTIEL et al., "Insulin signaling and the regulation of glucose and lipid metabolism," <i>Nature</i> 414 , pp. 799-806, 2001			
		BELL et al., "Diabetes mellitus and genetically programmed defects in β -cell function." <i>Nature</i> 414 , pp. 788-791 2001			
		MATHIS et al., " β -cell death during progression to diabetes." <i>Nature</i> 414 , pp. 792-798, 2001			
		SALTIEL, "New perspectives into the molecular pathogenesis and treatment of Type 2 diabetes," <i>Cell</i> 104 , pp. 517-529, 2001			
		MOLLER, "New drug targets for Type 2 diabetes and the metabolic syndrome," <i>Nature</i> 414 , pp. 821-827, 2001			
		BROWNLEE, "Biochemistry and molecular cell biology of diabetic complications," <i>Nature</i> 414 , pp. 813-820, 2001			
		HO et al., "Antioxidants, NF κ B activation, and diabetogenesis," <i>Proc. Soc. Exp. Biol. Med.</i> 222 , pp. 205-213, 1999			
		BODEN et al., "FFA cause hepatic insulin resistance by inhibiting suppression of glycogenolysis," <i>Am. J. Physiol. Endocrinol. Metab.</i> 283 , pp. E-12-E19, 2001			
		YU et al., "Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase in Muscle," <i>J. Biol. Chem.</i> 277 , pp. 50230-50236, 2002			
		MAEDLER et al., "Distinct effects of saturated and monounsaturated fatty acids on β -cell turnover and function," <i>Diabetes</i> 50 , pp. 69-76, 2001			
		PRADHAN et al., "C-reactive protein, interleukin 6, and risk of developing Type 2 diabetes mellitus," <i>JAMA</i> , 286 , pp. 327-334, 2001			
		THOMPSON et al., "Insulin modulation of acute-phase protein production in a human hepatoma cell line," <i>Cytokine</i> 3 , pp. 619-626, 1991			
		CAMPOS et al., "Insulin is a prominent modulator of the cytokine-stimulated expression of acute-phase plasma protein genes," <i>Mol. Cell. Biol.</i> 12 , 1789-1797, 1992			
▼		GANROT et al., "Serum concentration of α_2 -macroglobulin, haptoglobin and α_1 -antitrypsin in diabetes mellitus," <i>Acta Endocrinologica</i> 55 , pp. 537-544, 1967			

Examiner Signature	/Shirley Gembeh/	Date Considered	08/06/2009
--------------------	------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/582,391
(Use as many sheets as necessary)				Filing Date	July 14, 2006
				First Named Inventor	Zoltan Kiss
				Art Unit	16181618
				Examiner Name	Shirley V. Gembeh
Sheet	3	of	4	Attorney Docket Number	59496 - 336756

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
/S.G./		MCMILLAN, "Increased levels of acute-phase serum proteins in diabetes," <i>Metabolism</i> 38 , pp. 1042-1046, 1989			
		SCHMIDT et al., "Markers of inflammation and prediction of diabetes mellitus in adults," <i>The Lancet</i> 353 , pp. 1649-1652, 1999			
		JANCIAUSKIENE, "Conformational properties of serine proteinase inhibitors (serpins) confer multiple pathophysiological roles," <i>Biochim. Biophys. Acta</i> 1535 , pp. 221-235, 2001			
		WEWERS et al., "Replacement therapy for alpha ₁ -antitrypsin deficiency associated with emphysema," <i>N. Engl. J. Med.</i> 316 , pp. 1055-1062, 1987			
		PERRAUD et al., "Proliferation of rat astrocytes, but not of oligodendrocytes, is stimulated in vitro by protease inhibitors," <i>Int. J. Devl. Neuroscience</i> 6 , pp. 261-266, 1988			
		SHE et al., "alpha ₁ -antitrypsin can increase insulin-induced mitogenesis in various fibroblast and epithelial cell lines," <i>FEBS Lett.</i> 473 , pp. 33-36, 2000			
		DABBAGH et al., "Alpha-1-antitrypsin stimulates fibroblast proliferation and procollagen production and activates classical MAP kinase signaling pathways," <i>J. Cell. Physiol.</i> 186 , pp. 73-81, 2001			
		GRAZIADEI et al., "The acute phase protein alpha ₁ -antitrypsin inhibits growth and proliferation of human early erythroid progenitor cells (burst-forming units-erythroid) and of human erythroleukemic cells (K562) in vitro by interfering with transferring iron uptake," <i>Blood</i> 83 , pp. 260-268, 1994			
		YAVELOW et al., "alpha ₁ -antitrypsin blocks the release of transforming growth factor-alpha from MCF-7 human breast cancer cells," <i>J. Clin. Endocrinol. Metab.</i> 82 , pp. 745-752, 1997			
		OZEKI et al., "alpha ₁ -antitrypsin and hepatic fibrosis," <i>Br. J. Exp. Path.</i> 70 , pp. 143-152, 1989			
		GRAZIADEI, "Modulation of iron metabolism in monocytic THP-1 cells and cultured human monocytes by the acute-phase protein alpha ₁ -antitrypsin," <i>Exp. Hematol.</i> 26 , pp. 1053-1060, 1998			
		JANCIAUSKIENE et al., "An interaction between Gemfibrozil and alpha ₁ -antitrypsin," <i>J. Internal Med.</i> 236 , pp. 357-360, 1994			
		JANCIAUSKENE et al., "The interaction of hydrophobic bile acids with the alpha ₁ -proteinase inhibitor," <i>FEBS Lett.</i> 343 , pp. 141-145, 1994			
		JANCIAUSKIENE et al., "In vitro complex formation between cholesterol and alpha ₁ -proteinase inhibitor," <i>FEBS Lett.</i> 316 , pp. 269-272, 1993			

Examiner Signature	/Shirley Gembeh/	Date Considered	08/06/2009
--------------------	------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

<p>Substitute for form 1449B/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p><i>(Use as many sheets as necessary)</i></p>				<p>Complete if Known</p>	
				<i>Application Number</i>	10/582,391
				<i>Filing Date</i>	July 14, 2006
				<i>First Named Inventor</i>	Zoltan Kiss
				<i>Art Unit</i>	1618
				<i>Examiner Name</i>	Shirley V. Gembeh
Sheet	4	of	4	<i>Attorney Docket Number</i>	
59496 - 336756					

Examiner Signature	/Shirley Gembeh/	Date Considered	08/06/2009
--------------------	------------------	-----------------	------------

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.